Stirred has announced that it has been awarded a Platinum Medal from EcoVadis, placing it in the top 1% of companies globally ...

GSK’s new drug application for its investigational oral antibiotic gepotidacin has been accepted for priority review by the ...

AbbVie’s Parkinson’s disease (PD) therapy has been approved by the US Food and Drug Administration (FDA) to treat motor ...

Inizio Medical has announced the appointment of Matt Wadyka as president, US medical affairs. In this newly created role, ...

Amgen has shared positive top-line results from a late-stage trial of its B cell-depleting therapy Uplizna (inebilizumab-cdon ...

Patient Recruitment company, Innovative Trials, appointed new Finance and Business Services Director Innovative Trials have ...

Integration and creativity are at the core of our healthcare approach. Aided by our consumer driven insight, derived from our experience outside healthcare, we add an extra dimension in a regulated ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...

We partner with US and global medical affairs teams through a product’s life cycle to facilitate optimal collaboration between internal teams, physicians, and the broader medical community. This ...

Bristol Myers Squibb’s Opdivo (nivolumab) has been approved by the US Food and Drug Administration (FDA) as part of a perioperative treatment regimen for adults with non-small cell lung cancer (NSCLC) ...

Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a combination treatment for advanced breast cancer. The drug has been authorised ...

Pfizer has announced positive overall survival (OS) results from a late-stage study of its prostate cancer combination treatment. The phase 3 TALAPRO-2 trial has been evaluating the drugmaker’s PARP ...